Social Security Disability Insurance (SSDI)

Social Security Disability Insurance (SSDI) is a federal program that provides benefits to individuals who are unable to work due to a disability. Here are the key features of SSDI:

 

·      Eligibility: To be eligible for SSDI, you must have a disability that meets the Social Security Administration's (SSA)definition of disability, be unable to work, and have worked long enough and paid enough Social Security taxes to be insured for SSDI benefits.

 

·      Benefit Amount: The amount of your SSDI benefit is based on your average lifetime earnings prior to your disability and is paid monthly.

 

·      Medicare Eligibility: After receiving SSDI benefits for 24 months, you become eligible for Medicare.

 

·      Continuing Eligibility: To continue receivingSSDI benefits, you must meet certain medical and non-medical eligibility requirements, such as reporting changes in your medical condition, income, and work status to the SSA.

Next Up

According to Mployer Insights’ 2026 analysis of 76,000+ employer benefit plans, disability insurance remains a major market differentiator, with only 41% of U.S. employers offering short-term disability (STD) and 38% offering long-term disability (LTD). While 60% salary replacement serves as the national standard across both benefit types, standard plan designs disproportionately expose higher earners due to median benefit caps of $1,602/week for STD and $8,273/month for LTD. Furthermore, alignment between STD benefit durations (median 26 weeks) and LTD elimination periods (68% at 90 days) remains a critical area for plan structure optimization.
Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.